Is retatrutide available in Miami yet?

Key takeaways

Dr. Linda's take

I get some version of this question almost every week, usually from someone who saw a headline and felt a spark of hope. So let me give you the honest, non-hype answer first, and then the useful part.

The spark is understandable, since the early retatrutide data is genuinely striking. But retatrutide is not something you can get in Miami, or in Florida, or in the United States at all right now. It is still in clinical trials. The most helpful thing I can do is separate the two questions people are really asking: "Can I get retatrutide here yet?" and "What can I actually start now if I am ready?" The first answer is no, not yet. The second answer is where the good news lives.

What is available now versus retatrutide, at a glance

Here is the plain comparison, because the difference is really about approval status, not just which molecule is newest.

The short version is that the two medications most people have already heard of are the ones you can actually access, and the buzzy one is still in development. If you want the plain-language overview of the molecule itself, we cover it in what is retatrutide.

Is retatrutide approved yet?

No. Retatrutide is investigational, which means it has not been approved by the FDA and is not available by prescription anywhere in the United States, including Miami.

Investigational has a specific meaning. It is a medicine still being studied in clinical trials, one that has not cleared the review confirming its benefits outweigh its risks for general use. Until that happens, no pharmacy stocks it and no clinician can write you a prescription for it, in Miami or anywhere else.

If you see a website, clinic, or social post claiming to sell you "retatrutide" today, that is a reason for caution, not excitement, since an approved supply chain for it does not exist yet.

Why is there so much hype about retatrutide?

Because the early numbers are big. Most of what is known comes from one study, and it is worth understanding exactly what it did and did not show.

In a phase 2 trial, 338 adults with obesity were randomly assigned to receive retatrutide or placebo once weekly for 48 weeks. In the phase 2 trial, adults who received the highest 12-mg dose of retatrutide lost a least-squares mean of 24.2% of their body weight at 48 weeks, compared with 2.1% in the placebo group.

Two honest caveats sit alongside that headline. First, this is phase 2 data, which is earlier and smaller research designed mainly to find the right dose and check safety, and effect sizes can shift once a larger phase 3 program is complete. Second, the medicine is not free of trade-offs. In the trial, the most common adverse events with retatrutide were gastrointestinal, and they were dose-related and mostly mild to moderate in severity.

If you want a deeper look at those figures and what they mean, we break them down in what the retatrutide weight-loss numbers show.

What can you actually get in Miami right now?

This is the part that matters if you are ready to do something. Two approved medications for weight management are available by prescription across South Florida.

Semaglutide, sold as Wegovy, is approved by the FDA to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight who have at least one weight-related condition. Tirzepatide, sold as Zepbound, is approved by the FDA to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight who have at least one weight-related condition.

These are not consolation prizes. In the STEP 1 trial, semaglutide produced a mean weight loss of 14.9% over 68 weeks. In the phase 3 SURMOUNT-1 trial, tirzepatide produced a mean weight loss of up to 20.9% at the 15-mg dose over 72 weeks.

These were separate trials in different groups of people, run over different lengths of time, so the numbers cannot be lined up as a head-to-head race with retatrutide. What you can say fairly is that approved, available options already produce substantial results, and unlike retatrutide, you can start one now. For the local specifics of how that works, see how to get a prescription in Miami.

When might retatrutide actually reach Miami?

No one can give you an honest date. A medicine moves from phase 2 to a larger phase 3 program, and only after that data is reviewed and the FDA grants approval can it be sold and prescribed. That process takes years, not months, and not every promising phase 2 candidate finishes the journey.

So the truthful answer is that retatrutide could become available in Miami someday, on the same terms as the rest of the country, but there is no approval and no launch date now. Waiting for it is a choice to wait for something with no timeline, while approved options sit on the shelf today.

Frequently asked questions

Can I buy retatrutide in Miami right now?

No. Retatrutide is investigational and has not been approved by the FDA, so it is not sold at pharmacies and cannot be prescribed. The only legitimate way to receive it currently is by enrolling in a clinical trial.

Is a compounded or online "retatrutide" legitimate?

Approach any product marketed as retatrutide with caution. Since it is not FDA-approved, there is no approved, quality-controlled supply of it for prescriptions, and anything sold as retatrutide today falls outside that oversight. This is general education, so bring specific products you are curious about to a licensed clinician.

What is available in Miami instead?

Two FDA-approved medications for weight management are available by prescription in Miami: semaglutide (Wegovy) and tirzepatide (Zepbound). Both have strong trial results, and both are options a clinician can actually discuss with you now.

Is retatrutide better than what is available now?

It is too early to say. Its phase 2 numbers are eye-catching, but they can change in later trials. Retatrutide has never been studied head-to-head against the approved medications. Comparing early single-study data to established options is not an apples-to-apples comparison.

How do I know if I am a candidate for an approved option?

That depends on your health history and is a conversation for a licensed clinician. If you want a low-pressure starting point, our eligibility quiz can help you see whether an approved medication may be a fit.

References

1. The New England journal of medicine (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. PubMed PMID 37366315. https://pubmed.ncbi.nlm.nih.gov/37366315/ (Accessed 2026-07-22).
2. Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use: Prescribing Information (Indications and Usage). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-22).
3. Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use: Prescribing Information (Indications and Usage). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-22).
4. The New England journal of medicine (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. PubMed PMID 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/ (Accessed 2026-07-22).
5. The New England journal of medicine (2022). Tirzepatide Once Weekly for the Treatment of Obesity. PubMed PMID 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/ (Accessed 2026-07-22).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-22.*